Key Takeaways UTHR shares rose 12.5% after TETON-1 showed significant lung function improvement in IPF patients.The study met its primary endpoint with 130.1 mL FVC gain and reduced risk of clinical worsening.United Therapeutics plans an FDA filing by summer, backed by strong TETON-1 and TETON-2 results.Shares of United Therapeutics (UTHR) rallied 12.5% on Monday after the company unveiled robust data from the phase III TETON-1 study evaluating nebulized Tyvaso for the treatment of patients with idiopathic ...